How much profit has Mesoblast made this year?
Mesoblast has made -397.63 M USD this year.
Mesoblast Net Income 2025
Mesoblast Net Income
-397.63 M USD
Ticker
MSB.AX
ISIN
AU000000MSB8
WKN
A0DNPW
In 2025, Mesoblast's profit amounted to -397.63 M USD, a 352.08% increase from the -87.96 M USD profit recorded in the previous year.
The Mesoblast Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2031e | - |
| 2030e | - |
| 2029e | - |
| 2028e | -1 |
| 2027e | 7.3 |
| 2026e | -220.99 |
| 2025e | -397.63 |
| 2024 | -87.96 |
| 2023 | -81.89 |
| 2022 | -91.35 |
| 2021 | -98.81 |
| 2020 | -77.94 |
| 2019 | -89.8 |
| 2018 | -35.29 |
| 2017 | -76.82 |
| 2016 | -4.13 |
| 2015 | -96.24 |
| 2014 | -74.28 |
| 2013 | -63.23 |
| 2012 | -73.36 |
| 2011 | 89.36 |
| 2010 | -13.01 |
| 2009 | -9.03 |
| 2008 | -9 |
| 2007 | -6.85 |
| 2006 | -6.2 |
| 2005 | -1.14 |
Mesoblast Revenue, EBIT, Net Income AU000000MSB8 · A0DNPW
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Mesoblast, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mesoblast from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mesoblast’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Mesoblast. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Mesoblast’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Mesoblast’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mesoblast’s growth potential.
Mesoblast Revenue, EBIT and net profit per share
| Date | Mesoblast Revenue | Mesoblast EBIT | Mesoblast Net Income |
|---|---|---|---|
| 2031e | 1.28 B undefined | 0 undefined | 0 undefined |
| 2030e | 867.77 M undefined | 337.82 M undefined | 0 undefined |
| 2029e | 607.24 M undefined | 244.59 M undefined | 0 undefined |
| 2028e | 672.29 M undefined | 80.19 M undefined | -996,569.93 undefined |
| 2027e | 245.6 M undefined | 101.07 M undefined | 7.3 M undefined |
| 2026e | 67.75 M undefined | -43.63 M undefined | -220.99 M undefined |
| 2025e | 16.36 M undefined | -66.59 M undefined | -397.63 M undefined |
| 2024 | 5.9 M undefined | -66.89 M undefined | -87.96 M undefined |
| 2023 | 7.5 M undefined | -62.72 M undefined | -81.89 M undefined |
| 2022 | 10.21 M undefined | -73.76 M undefined | -91.35 M undefined |
| 2021 | 7.46 M undefined | -90.39 M undefined | -98.81 M undefined |
| 2020 | 32.16 M undefined | -73.49 M undefined | -77.94 M undefined |
| 2019 | 16.72 M undefined | -86.47 M undefined | -89.8 M undefined |
| 2018 | 17.34 M undefined | -64.31 M undefined | -35.29 M undefined |
| 2017 | 2.41 M undefined | -90.17 M undefined | -76.82 M undefined |
| 2016 | 42.55 M undefined | -18.47 M undefined | -4.13 M undefined |
| 2015 | 19.76 M undefined | -91.79 M undefined | -96.24 M undefined |
| 2014 | 23.84 M undefined | -67.85 M undefined | -74.28 M undefined |
| 2013 | 29.52 M undefined | -61.6 M undefined | -63.23 M undefined |
| 2012 | 39.34 M undefined | -50.24 M undefined | -73.36 M undefined |
| 2011 | 18.99 M undefined | -7.79 M undefined | 89.36 M undefined |
| 2010 | 660,000 undefined | -9.14 M undefined | -13.01 M undefined |
| 2009 | 650,000 undefined | -6.93 M undefined | -9.03 M undefined |
| 2008 | 810,000 undefined | -7.1 M undefined | -9 M undefined |
| 2007 | 1.32 M undefined | -5.5 M undefined | -6.85 M undefined |
| 2006 | 2.11 M undefined | -4.7 M undefined | -6.2 M undefined |
| 2005 | 380,000 undefined | -780,000 undefined | -1.14 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 380,000 USD | -780,000 USD | -1.14 M USD |
| 2006 | 2.11 M USD | -4.7 M USD | -6.2 M USD |
| 2007 | 1.32 M USD | -5.5 M USD | -6.85 M USD |
| 2008 | 810,000 USD | -7.1 M USD | -9 M USD |
| 2009 | 650,000 USD | -6.93 M USD | -9.03 M USD |
| 2010 | 660,000 USD | -9.14 M USD | -13.01 M USD |
| 2011 | 18.99 M USD | -7.79 M USD | 89.36 M USD |
| 2012 | 39.34 M USD | -50.24 M USD | -73.36 M USD |
| 2013 | 29.52 M USD | -61.6 M USD | -63.23 M USD |
| 2014 | 23.84 M USD | -67.85 M USD | -74.28 M USD |
| 2015 | 19.76 M USD | -91.79 M USD | -96.24 M USD |
| 2016 | 42.55 M USD | -18.47 M USD | -4.13 M USD |
| 2017 | 2.41 M USD | -90.17 M USD | -76.82 M USD |
| 2018 | 17.34 M USD | -64.31 M USD | -35.29 M USD |
| 2019 | 16.72 M USD | -86.47 M USD | -89.8 M USD |
| 2020 | 32.16 M USD | -73.49 M USD | -77.94 M USD |
| 2021 | 7.46 M USD | -90.39 M USD | -98.81 M USD |
| 2022 | 10.21 M USD | -73.76 M USD | -91.35 M USD |
| 2023 | 7.5 M USD | -62.72 M USD | -81.89 M USD |
| 2024 | 5.9 M USD | -66.89 M USD | -87.96 M USD |
| 2025e | 16.36 M USD | -66.59 M USD | -397.63 M USD |
| 2026e | 67.75 M USD | -43.63 M USD | -220.99 M USD |
| 2027e | 245.6 M USD | 101.07 M USD | 7.3 M USD |
| 2028e | 672.29 M USD | 80.19 M USD | -996,569.93 USD |
| 2029e | 607.24 M USD | 244.59 M USD | 0 USD |
| 2030e | 867.77 M USD | 337.82 M USD | 0 USD |
| 2031e | 1.28 B USD | 0 USD | 0 USD |
Mesoblast stock margins AU000000MSB8 · A0DNPW
The Mesoblast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mesoblast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mesoblast.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Mesoblast's sales revenue. A higher gross margin percentage indicates that the Mesoblast retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Mesoblast's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Mesoblast's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mesoblast's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mesoblast. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mesoblast's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Mesoblast Margin History
| Mesoblast Gross margin | Mesoblast Profit margin | Mesoblast EBIT margin | Mesoblast Profit margin |
|---|---|---|---|
| 2031e | -166.3 % | 0 % | 0 % |
| 2030e | -166.3 % | 38.93 % | 0 % |
| 2029e | -166.3 % | 40.28 % | 0 % |
| 2028e | -166.3 % | 11.93 % | -0.15 % |
| 2027e | -166.3 % | 41.15 % | 2.97 % |
| 2026e | -166.3 % | -64.4 % | -326.2 % |
| 2025e | -166.3 % | -406.99 % | -2,430.21 % |
| 2024 | -166.3 % | -1,133.28 % | -1,490.27 % |
| 2023 | -269.72 % | -836.2 % | -1,091.71 % |
| 2022 | -201.13 % | -722.17 % | -894.33 % |
| 2021 | -338.83 % | -1,212.27 % | -1,325.25 % |
| 2020 | 21.29 % | -228.55 % | -242.38 % |
| 2019 | 8.16 % | -517.08 % | -537.01 % |
| 2018 | 68.24 % | -370.85 % | -203.51 % |
| 2017 | -400.21 % | -3,738.47 % | -3,184.7 % |
| 2016 | 30.05 % | -43.4 % | -9.7 % |
| 2015 | -20.35 % | -464.52 % | -487.04 % |
| 2014 | -6.25 % | -284.61 % | -311.58 % |
| 2013 | 27.24 % | -208.67 % | -214.19 % |
| 2012 | 42.3 % | -127.71 % | -186.48 % |
| 2011 | -166.3 % | -41.02 % | 470.56 % |
| 2010 | -166.3 % | -1,384.85 % | -1,971.21 % |
| 2009 | -166.3 % | -1,066.15 % | -1,389.23 % |
| 2008 | -166.3 % | -876.54 % | -1,111.11 % |
| 2007 | -166.3 % | -416.67 % | -518.94 % |
| 2006 | -166.3 % | -222.75 % | -293.84 % |
| 2005 | -166.3 % | -205.26 % | -300 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | -166.3 % | -205.26 % | -300 % |
| 2006 | -166.3 % | -222.75 % | -293.84 % |
| 2007 | -166.3 % | -416.67 % | -518.94 % |
| 2008 | -166.3 % | -876.54 % | -1,111.11 % |
| 2009 | -166.3 % | -1,066.15 % | -1,389.23 % |
| 2010 | -166.3 % | -1,384.85 % | -1,971.21 % |
| 2011 | -166.3 % | -41.02 % | 470.56 % |
| 2012 | 42.3 % | -127.71 % | -186.48 % |
| 2013 | 27.24 % | -208.67 % | -214.19 % |
| 2014 | -6.25 % | -284.61 % | -311.58 % |
| 2015 | -20.35 % | -464.52 % | -487.04 % |
| 2016 | 30.05 % | -43.4 % | -9.7 % |
| 2017 | -400.21 % | -3,738.47 % | -3,184.7 % |
| 2018 | 68.24 % | -370.85 % | -203.51 % |
| 2019 | 8.16 % | -517.08 % | -537.01 % |
| 2020 | 21.29 % | -228.55 % | -242.38 % |
| 2021 | -338.83 % | -1,212.27 % | -1,325.25 % |
| 2022 | -201.13 % | -722.17 % | -894.33 % |
| 2023 | -269.72 % | -836.2 % | -1,091.71 % |
| 2024 | -166.3 % | -1,133.28 % | -1,490.27 % |
| 2025e | -166.3 % | -406.99 % | -2,430.21 % |
| 2026e | -166.3 % | -64.4 % | -326.2 % |
| 2027e | -166.3 % | 41.15 % | 2.97 % |
| 2028e | -166.3 % | 11.93 % | -0.15 % |
| 2029e | -166.3 % | 40.28 % | 0 % |
| 2030e | -166.3 % | 38.93 % | 0 % |
| 2031e | -166.3 % | 0 % | 0 % |
Mesoblast Aktienanalyse
What does Mesoblast do?
Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Mesoblast's Profit Margins
The profit margins of Mesoblast represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Mesoblast's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Mesoblast's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Mesoblast's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Mesoblast’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Mesoblast stock
How has the profit developed compared to last year?
The profit has increased by 352.08% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Mesoblast publish its earnings?
Mesoblast publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Mesoblast?
The profits of Mesoblast are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Mesoblast?
You can learn more about the earnings of Mesoblast by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Mesoblast pay?
Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.
What is the dividend yield of Mesoblast?
The current dividend yield of Mesoblast is .
When does Mesoblast pay dividends?
Mesoblast pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mesoblast?
Mesoblast paid dividends every year for the past 0 years.
What is the dividend of Mesoblast?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mesoblast located?
Mesoblast is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mesoblast from 7/30/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/30/2025.
When did Mesoblast pay the last dividend?
The last dividend was paid out on 7/30/2025.
What was the dividend of Mesoblast in the year 2024?
In the year 2024, Mesoblast distributed 0 USD as dividends.
In which currency does Mesoblast pay out the dividend?
The dividends of Mesoblast are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mesoblast
Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
